Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Wize Pharma Inc (WIZP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 5,845
  • Shares Outstanding, K 10,254
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1000 +381.00%
on 05/31/19
0.7500 -35.87%
on 05/22/19
-0.0990 (-17.07%)
since 05/17/19
3-Month
0.1000 +381.00%
on 05/31/19
1.2200 -60.57%
on 04/29/19
-0.1290 (-21.15%)
since 03/18/19
52-Week
0.1000 +381.00%
on 05/31/19
6.1000 -92.11%
on 07/13/18
-5.5090 (-91.97%)
since 06/15/18

Most Recent Stories

More News
Wize Pharma Interview to Air on Bloomberg International on the RedChip Money Report June 16, 2019

Wize Pharma, Inc. (OTCQB: WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced an interview with its CEO, Noam Danenberg, will air on The RedChip...

WIZP : 0.4810 (-15.61%)
Wize Pharma Interview to Air on Bloomberg International on the RedChip Money Report June 16, 2019

LOS ANGELES , June 14, 2019 /PRNewswire/ -- Wize Pharma, Inc. (OTCQB: WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced an interview...

WIZP : 0.4810 (-15.61%)
Wize Pharma Announces Positive Results in First Controlled Study of Treatment for Dry Eye Syndrome in Patients With Conjunctivochalasis

Wize Pharma, Inc. (OTCQB: WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced completion of statistical analysis of the Phase II clinical...

WIZP : 0.4810 (-15.61%)
Wize Pharma Announces Positive Results in First Controlled Study of Treatment for Dry Eye Syndrome in Patients With Conjunctivochalasis

WIZP : 0.4810 (-15.61%)
Wize Pharma's CEO Noam Danenberg Increases Stake in Company

Wize Pharma, Inc. ("Wize Pharma" or the "Company") (OTCQB: WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, announced today the Company's Chief Executive...

WIZP : 0.4810 (-15.61%)
Wize Pharma Appoints Mark Sieczkarek as Chairman of the Board, Noam Danenberg to Become Chief Executive Officer

Wize Pharma, Inc. ("Wize Pharma" or the "Company") (OTCQB: WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, is pleased to announce that Mr. Mark Sieczkarek...

WIZP : 0.4810 (-15.61%)
LO2A Licensor, Resdevco, Granted Market Approval for the Treatment of Sjögren's Syndrome in Hungary

HOD HASHARON, Israel, March 11, 2019 /PRNewswire/ --  Wize Pharma, Inc.  ("Wize Pharma" or the "Company") (OTCQB: WIZP) a clinical-stage biopharmaceutical company focused on the treatment of...

WIZPD : 3.7400 (unch)
WIZP : 0.4810 (-15.61%)
Wize Pharma, Inc. Closes Deal to Launch Joint Venture With Cannabics

Wize Pharma, Inc. ("Wize Pharma" or the "Company") (OTCQB: WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced that the Company closed a deal...

WIZP : 0.4810 (-15.61%)
CNBX : 0.2800 (+0.36%)
Cannabics Pharmaceuticals Closes Agreement With Wize Pharma

BETHESDA, Maryland and TEL AVIV, Israel, March 6, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) a world leader in personalized cannabinoid medicine focused on cancer and its...

WIZP : 0.4810 (-15.61%)
CNBX : 0.2800 (+0.36%)
Cannabics Pharmaceuticals Closes Agreement With Wize Pharma

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) a world leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has closed an agreement with Wize Pharma,...

WIZP : 0.4810 (-15.61%)
CNBX : 0.2800 (+0.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade WIZP with:

Key Turning Points

2nd Resistance Point 0.6003
1st Resistance Point 0.5407
Last Price 0.4810
1st Support Level 0.4507
2nd Support Level 0.4203

See More

52-Week High 6.1000
Fibonacci 61.8% 3.8080
Fibonacci 50% 3.1000
Fibonacci 38.2% 2.3920
Last Price 0.4810
52-Week Low 0.1000

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar